Menopause Hormone Therapy (HRT) in Royal Oak, MI

Bioidentical hormones in Royal Oak: what it means

Behind the label "bioidentical hormone replacement therapy" is a plain idea: a hormone whose structure matches the body's own. Two hormones used in menopause care fit it exactly, estradiol and micronized progesterone. FDA-approved versions of both are sold by prescription at retail pharmacies.

"BHRT" often means compounded hormones, a cream, a blend such as Bi-Est or a pellet that a pharmacy mixes for one prescription. They are not FDA-approved, which means the FDA cannot assure their safety or effectiveness. The FDA says it has no evidence that compounded "bioidentical hormones" are safe and effective, or more effective than FDA-approved hormone therapy. The National Academies, reviewing them for the FDA in 2020, called their wide use a public health concern.

For women in Royal Oak, a physician licensed in Michigan can prescribe estradiol (pill, patch, cream or vaginal) and progesterone when they fit your history. There are no pellets. The pharmacy that fills VevaMD prescriptions also compounds, so ask your physician whether yours is an FDA-approved product or compounded. Two options are compounded for certain: testosterone cream for women and Bi-Est are not FDA-approved.

The NPI registry counts 76 OB-GYNs practicing in Royal Oak, about 131.3 for every 100,000 residents against 17.8 nationally and above Michigan's 21.0, a higher rate than 98% of the cities VevaMD covers. That is about 90 women aged 45 to 64 for each OB-GYN in the city, a ratio rather than a count of open appointments.

Counting the area around it, 351 OB-GYNs practice in Royal Oak or within 10 miles and 966 within 25 miles: 26.1 for every 100,000 of the 3,697,770 people who live within 25 miles, a dense supply. Whether or not you have an OB-GYN, you can ask a physician licensed in Michigan about menopause hormone therapy online from Royal Oak, with no waiting room.

A pellet clinic is a different model: it implants a hormone pellet under the skin during a visit, and compounded pellets are not FDA-approved. The Endocrine Society points to a study that found hormone levels well above the expected range in women using them. ACOG's guidance is to prefer FDA-approved menopause hormone therapy to compounded hormones.

Sources: FDA: Menopause · FDA: National Academies study of compounded bioidentical hormones (2020) · Endocrine Society position statement on compounded bioidentical hormones (2019) · ACOG Clinical Consensus No. 6, compounded bioidentical menopausal hormone therapy (2023) · CMS NPPES NPI full file, 2026-10-11